The U.S. Food and Drug Administration approved on Wednesday the lupus treatment Benlysta developed by Human Genome Sciences Inc. (NASDAQ ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE